Novartis’s anti-CD20 monoclonal antibody has been shown to increase the odds of patients with multiple sclerosis achieving no evidence of disease activity status by more than 3-fold in the first year and more than 8-fold in the second year. from Front page feed https://ift.tt/2z5v0KG
Helius’s short-term treatment PoNS device has been approved for use in Canada, and is intended to be used alongside physical therapy for gait deficit due to mild and moderate symptoms of MS. from Front page feed https://ift.tt/2M3j9zr
Avadel seeks to have its sodium oxybate agent be the first once-nightly therapy to address both excessive daytime sleepiness and cataplexy in patients with narcolepsy. from Front page feed https://ift.tt/3di8opf
Amid swirling reports of associations between stroke and the novel coronavirus, as well as the impact the pandemic has had on stroke care, new recommendations to maintain care expectations have been suggested by a diverse group of stroke experts. from Front page feed https://ift.tt/2ZJi6gb
The new data further cemented the therapy’s consistent safety profile from previous studies as well as demonstrated a newfound durability in patients with later-onset spinal muscular atrophy. from Front page feed https://ift.tt/3dhFyoA
During the COVID-19 pandemic, it is more important than ever to ensure that a patient with stroke is transferred to the right hospital the first time around. from Front page feed https://ift.tt/2X4X2iw
This retrospective cohort study suggests that rituximab is more effective than conventional immunotherapy and might most impactful if initiated within 12 months of symptom onset in myasthenia gravis. from Front page feed https://ift.tt/2T10jNg
The COX-2 inhibitor was OK’d for the treatment of acute migraine in adults with or without aura more than 20 years after the drug's initial approval for pain indications. from Front page feed https://ift.tt/3dwsnQC
The COX-2 inhibitor was OK’d for the treatment of acute migraine in adults with or without aura more than 20 years after the drug's initial approval for pain indications. from Front page feed https://ift.tt/2YVPZtL
The exercise and physical activity recommendations were tailored to individuals with differing disability levels on the Expanded Disability Status Scale. from Front page feed https://ift.tt/2YWpgxf
Biohaven’s acute migraine treatment rimegepant showed numerically significant differences from placebo on pain relief, with benefit as early as 15 minutes postdose. from Front page feed https://ift.tt/3cgG062
The initial report of the US Expanded Access Program for fenfluramine indicates that those with Dravet syndrome treated with fenfluramine (Fintepla; Zogenix) have clinically meaningful responses similar to that observed in clinical trials. from Front page feed https://ift.tt/2WfD9ox
In addition to increased motor milestone achievement, the safety profile of risdiplam was consistent with that observed in previous studies, with no new safety signals identified. from Front page feed https://ift.tt/2zk9qSi
In addition to increased motor milestone achievement, the safety profile of risdiplam was consistent with that observed in previous studies, with no new safety signals identified. from Front page feed https://ift.tt/3fvkEEd
The Novartis agent showed significant reduction of migraine days in both the real-world TELESCOPE and PERISCOPE studies in patients with migraine. from Front page feed https://ift.tt/2W96eAy
The Idorsia drug candidate demonstrated minimal serious treatment-emergent adverse events, with no rebound insomnia or withdrawal symptoms upon discontinuation. from Front page feed https://ift.tt/2Yaipjv